Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated:  12/31/1969
START (South Texas Accelerated Research Therapeutics)
1182
mi
from 91732
San Antonio, TX
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated: 12/31/1969
START (South Texas Accelerated Research Therapeutics)
1182
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
961
mi
from 91732
Seattle, WA
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated:  12/31/1969
Istituto Clinico Humanitas
mi
from 91732
Milan,
Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion
Status: Enrolling
Updated: 12/31/1969
Istituto Clinico Humanitas
mi
from 91732
Milan,
Click here to add this to my saved trials
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
2375
mi
from 91732
Philadelphia, PA
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
21
mi
from 91732
Orange, CA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
21
mi
from 91732
Orange, CA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2103
mi
from 91732
Gainesville, FL
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2103
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1338
mi
from 91732
Westwood, KA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1338
mi
from 91732
Westwood, KA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1655
mi
from 91732
New Orleans, LA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1655
mi
from 91732
New Orleans, LA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2611
mi
from 91732
Scarborough, ME
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2611
mi
from 91732
Scarborough, ME
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1966
mi
from 91732
Detroit, MI
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1966
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1511
mi
from 91732
Minneapolis, MN
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2430
mi
from 91732
Hackensack, NJ
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2430
mi
from 91732
Hackensack, NJ
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1400
mi
from 91732
Galveston, TX
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1400
mi
from 91732
Galveston, TX
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Research Site
6113
mi
from 91732
Ciudad Autónoma de Buenos Aires,
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Research Site
6113
mi
from 91732
Ciudad Autónoma de Buenos Aires,
Click here to add this to my saved trials
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2281
mi
from 91732
Washington,
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forest University
2129
mi
from 91732
Winston-Salem, NC
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forest University
2129
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
2445
mi
from 91732
Harrison, NY
Clinical and Histopathologic Characteristics of BAP1 Mutations
Clinical and Histopathologic Characteristics of BAP1 Mutations
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
2445
mi
from 91732
Harrison, NY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
21
mi
from 91732
Orange, CA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
21
mi
from 91732
Orange, CA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
825
mi
from 91732
Aurora, CO
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2103
mi
from 91732
Gainesville, FL
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2103
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1813
mi
from 91732
Louisville, KY
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2540
mi
from 91732
Worcester, MA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2540
mi
from 91732
Worcester, MA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1511
mi
from 91732
Minneapolis, MN
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2245
mi
from 91732
Rochester, NY
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2245
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2119
mi
from 91732
Pittsburgh, PA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2119
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2119
mi
from 91732
Pittsburgh, PA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2119
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2267
mi
from 91732
Richmond, VA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2267
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
6084
mi
from 91732
Pilar,
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
6084
mi
from 91732
Pilar,
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2281
mi
from 91732
Washington,
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials